CoronaVac: more data for regulators and policy makers
- PMID: 34246359
- PMCID: PMC8266267
- DOI: 10.1016/S0140-6736(21)01543-9
CoronaVac: more data for regulators and policy makers
Comment on
-
Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey.Lancet. 2021 Jul 17;398(10296):213-222. doi: 10.1016/S0140-6736(21)01429-X. Epub 2021 Jul 8. Lancet. 2021. PMID: 34246358 Free PMC article. Clinical Trial.
References
-
- WHO WHO coronavirus (COVID-19) dashboard. July 6, 2021. https://covid19.who.int
-
- Plotkin S, Orenstein W, Offit P. 5th edn. Saunders/Elsevier; Philadelphia, PA: 2008. Vaccines.
-
- WHO Status of COVID-19 vaccines within WHO EUL/PQ evaluation process. June 16, 2021. https://extranet.who.int/pqweb/sites/default/files/documents/Status_of_C...
-
- Tanriover MD, Doğanay HL, Akova M, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021 doi: 10.1016/S0140-6736(21)01429-X. published online July 8. - DOI - PMC - PubMed
-
- WHO . World Health Organisation; Geneva: 2020. WHO target product profiles for COVID-19 vaccines: version 3.https://www.who.int/publications/m/item/who-target-product-profiles-for-...
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources